SEC Contract Filing

Filing Date: 2019-03-13

Document Content:
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>16
<FILENAME>d702482dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Execution Copy </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 TO LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 to License Agreement (this &#147;<B>Amendment</B>&#148;) is dated as of October&nbsp;23, 2014 (the
&#147;<B>Amendment Effective Date</B>&#148;) by and between <B>Genzyme Corp</B>., a corporation having an address at 500 Kendall Street, Cambridge, MA 02142 (&#147;<B>Genzyme</B>&#148; or &#147;<B>Licensor</B>&#148;) and X<B>4 Pharmaceuticals,
INC</B>., a Delaware corporation having an address at 281 School Street, Belmont, MA 02478, United States (&#147;<B>X4</B>&#148;). Each of Genzyme and X4 may be referred to herein as a &#147;<B>Party</B>&#148; and together as the
&#147;<B>Parties</B>&#148;. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement by and between the Parties effective as of July&nbsp;10, 2014 (the
&#147;<B>Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties hereto desire to amend the Agreement as set forth herein to, among other things,
include the right of X4 to extend a certain milestone date and to reflect the conversion of X4 from a limited liability company to a corporation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;13.8 of the Agreement, the Agreement may be amended by a written instrument duly executed by authorized
representatives of both Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and
valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments to Agreement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The reference in the first recital to &#147;<B>X4 Pharmaceuticals, LLC</B>, a Massachusetts limited liability
company&#148; is hereby deleted and &#147;<B>X4 Pharmaceuticals, INC</B>., a Delaware corporation&#148; is hereby inserted in lieu thereof </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All references in the Agreement to &#147;X4 Pharmaceuticals, LLC&#148; are hereby deleted and &#147;X4
Pharmaceuticals, INC.&#148; is hereby inserted in lieu thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Section 6.2 of the Agreement is hereby deleted
in its entirety and the following is hereby inserted in lieu thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;6.2&nbsp;&nbsp;&nbsp;&nbsp;X4 First Financing Fee. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;No later than [***] after the closing of the X4 First Financing, X4 shall pay Genzyme an
upfront amount equal to Three Hundred Thousand Dollars ($300,000) (the &#147;<B>First Financing Fee</B>&#148;). The payment of the First Financing Fee shall be [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;X4 shall have the right in its sole discretion to extend the Financing Exclusivity Period
(as defined in Section&nbsp;12.1.1 below) during the term thereof by providing written notice to Genzyme (the &#147;<B>Financing Exclusivity Extension Notice</B>&#148;) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 of 3 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission
pursuant to the Registrant&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </P>

</DIV></Center>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Section 6.3.1(a) of the Agreement is hereby deleted in its
entirety and the following is hereby inserted in lieu thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Initial Grant</U>. No
later than [***] after the closing of the X4 Firs